NEO (NeoGenomics) Quality Rank


NEO NeoGenomics Inc NEO
72 GF Score
Price $14.50
GF Value $16.62
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

NeoGenomics Quality Rank Related Terms

NEO
72GF Score
NeoGenomics Inc NEO
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is NeoGenomics (NEO) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be undervalued. The current stock price of $14.50 is trading 12.8% below its estimated GF Value™ of $16.62. GuruFocus considers NeoGenomics to be Modestly Undervalued.

Key valuation signals for NEO:

  • Quality Rank:
  • GF Value™: $16.62 vs. price of $14.50 (12.8% below fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the NEO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

NeoGenomics Business Description

Other Exchanges NEO:MexicoNG9:Germany
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
72GF Score

Get the complete analysis for NEO

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.50
Price
$16.62
GF Value